Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
Lawler CP et al. (1999). „Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes”. Neuropsychopharmacology20 (6): 612–27. DOI:10.1016/S0893-133X(98)00099-2. PMID10327430.
Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR (December 2005). „Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist”. J Pharmacol Exp Ther315 (3): 1278–87. DOI:10.1124/jpet.105.092155. PMID16135699.
Jordan, S et al. (2002). „The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor”. Eur J Pharmacol441 (3): 137–140. DOI:10.1016/S0014-2999(02)01532-7. PMID12063084.
Shapiro, DA et al. (2003). „Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology”. Neuropsychopharmacology28 (8): 1400–1411. DOI:10.1038/sj.npp.1300203. PMID12784105.
Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (February 2006). „Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms”. Biochem Pharmacol71 (4): 521–9. DOI:10.1016/j.bcp.2005.11.007. PMID16336943.
Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
Lawler CP et al. (1999). „Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes”. Neuropsychopharmacology20 (6): 612–27. DOI:10.1016/S0893-133X(98)00099-2. PMID10327430.
Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR (December 2005). „Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist”. J Pharmacol Exp Ther315 (3): 1278–87. DOI:10.1124/jpet.105.092155. PMID16135699.
Jordan, S et al. (2002). „The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor”. Eur J Pharmacol441 (3): 137–140. DOI:10.1016/S0014-2999(02)01532-7. PMID12063084.
Shapiro, DA et al. (2003). „Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology”. Neuropsychopharmacology28 (8): 1400–1411. DOI:10.1038/sj.npp.1300203. PMID12784105.
Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (February 2006). „Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms”. Biochem Pharmacol71 (4): 521–9. DOI:10.1016/j.bcp.2005.11.007. PMID16336943.